Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients

Prostate Cancer and Prostatic Diseases volume 7, pages 350–354 (2004)Cite this article

Abstract

Introduction: Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with bone lysis by osteoclast proliferation, paralleling nearby bone deposition. The treatment options are palliative and have poor clinical response with short-lived improvement. We have studied the clinical effect of bisphosphonates (clodronate) in the treatment of skeletal complications from prostate cancer.

Materials and Methods: In an open prospective study, 58 patients with hormone-refractory prostate cancer with bone metastases were assessed from November 2000 to September 2003. The mean age was 70.3 y (range: 51–87 y). Bone scintigraphy, plain X-ray, assaying of prostate-specific antigen (PSA) and biochemical tests were requested before and following treatment. Patients were previously and subsequently assessed using the visual pain scale (0–10) and Karnofsky's index after the first and second intravenous (i.v.) infusions (administration of i.v. clodronate every 28 days) and every 4–6 months thereafter. Student's t-test was used for statistical analysis.

Results: A total of 53 patients (91.4%) showed improvement after the first and/or second cycle, which persisted for at least 4 months (average 6.3 months). The averages on the visual pain scale improved from 7.4 (range: 2–8) to 2.4 (0–7) and on Karnofsky's index from 43 (32–58) to 73 (50–82). The radiological appearance of the metastases improved in 27 patients (46.5%) and there were few relapses (six patients; 10.3%).

Conclusions: Clodronate was effective in the treatment of skeletal complications from prostate cancer. There was an objective response in 91.4% of treated patients, with a marked improvement in the subjective visual pain scale evaluation as well as on Karnofsky's index, with low side effects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Berruti A et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248–1253.

    Article  CAS  Google Scholar 

  2. Greenlee RT, Murray T, Bolden S . Cancer statistics, 2000. American Cancer Society, January/February 2000; 50: 6–11.

  3. Parker SL, Tong T, Bolden S . Cancer statistics 1997. Cancer J Clin 1997; 47: 5–6.

    Article  CAS  Google Scholar 

  4. Issacs JT . The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26: 263–269.

    Article  Google Scholar 

  5. Smith Jr JA, Soloway MS, Young MJ . Complications of advanced prostate cancer. Urology 1999; 54: 8–12.

    Article  Google Scholar 

  6. Guise TA, Mundy GR . Cancer and bone. Endocr Rev 1998; 19: 18–54.

    CAS  PubMed  Google Scholar 

  7. Dodwell DJ . Malignant bone resorption: cellular and biochemical mechanisms. Ann oncol 1992; 3: 257–267.

    Article  CAS  Google Scholar 

  8. Powles T et al. Controled trial of clodronate in patient with primary operable breast cancer. J Clin Oncol 2002; 20: 3219–3224.

    Article  CAS  Google Scholar 

  9. Orr F, Lee J, Duivenvoorden WC . Pathophysiologic interactions in skeletal metastasis. Cancer, Suppl 2000; 88: 2912–2915.

    Article  CAS  Google Scholar 

  10. Sansoni P, Passeri G, Fangnoni F . Inhibition of antigen presenting and cell function by alendronate in vitro. J. Bone Miner Res 1995; 10: 1719–1723.

    Article  CAS  Google Scholar 

  11. Lissoni P, Cazzanigna M, Barni, Derenne S . Acute effect of pamidronate administration on serum levels of interleukin-6 in advanced solid tumor patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. Eur J Cancer 1992; 33: 304–308.

    Article  Google Scholar 

  12. Diel IJ, Solomayer EF, Costa SD . Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357–363.

    Article  CAS  Google Scholar 

  13. Luckman SP, Huges DE, Loxon FF . Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins including Ras. J Bone Miner Res 1998; 13: 581–589.

    Article  CAS  Google Scholar 

  14. Adami S, Salvagno G, Guarrera G . Dichloromethylene—biphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985; 134: 1152–1155.

    Article  CAS  Google Scholar 

  15. Vorreuther R . Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol 1993; 72: 792–795.

    Article  CAS  Google Scholar 

  16. Heidenreich A, Hofmann R, Engelmann UH . The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001; 165: 136–140.

    Article  CAS  Google Scholar 

  17. Dearnaley DP et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003; 95: 1300–1311.

    Article  CAS  Google Scholar 

  18. Munoy GR . Bisphosphonates and tumor burden. J Clin Oncol 2002; 20: 3191–3192.

    Article  Google Scholar 

  19. Smith Jr JA . Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of randomized, prospective, double-blind placebo controlled study. J Urol 1989; 141: 85–87.

    Article  Google Scholar 

  20. Jagdev SP et al. Comparison of effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption with metastatic bone disease. Ann Oncol 2001; 12: 1433–1438.

    Article  CAS  Google Scholar 

  21. Ernst DS et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/predinisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003; 21: 3335–3342.

    Article  CAS  Google Scholar 

  22. Saad F et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–1468.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Beneficência Portuguesa Hospital of São Paulo and Santa Helena Hospital of São Paulo, São Paulo, SP, Brazil

    P Rodrigues, F Hering & J C Campagnari

Authors
  1. P Rodrigues
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Hering
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J C Campagnari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Rodrigues.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodrigues, P., Hering, F. & Campagnari, J. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Prostate Cancer Prostatic Dis 7, 350–354 (2004). https://doi.org/10.1038/sj.pcan.4500752

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500752

Keywords

This article is cited by

Search

Advanced search

Quick links